Introduction {#Sec1}
============

The current use of prescription drugs is suboptimal. Many patients suffer from poor drug efficacy which in turn can lead to cessation of therapy or disease progression. Another significant portion of patients experience serious drug adverse events with possible hospitalization or even death as a result of the current one-size-fits-all approach \[[@CR1], [@CR2]\]. In recent decades, it has become clear that the interpatient variability in drug efficacy and toxicity can be (partially) explained by genetic variation between individuals \[[@CR3], [@CR4]\]. Therefore, in 2005, the Royal Dutch Pharmacists Association formed the Dutch Pharmacogenetics Working Group (DPWG) to aid in the personalization of pharmacotherapy based on an individual's genetic makeup. The DPWG has created a set of evidence-based guidelines (*n* = 86) which have been fully integrated into the electronic drug prescribing and dispensing systems and are available through clinical decision support \[[@CR5]--[@CR7]\]. Currently, in The Netherlands, pharmacogenetics (PGx) testing is mostly performed for single gene-drug pairs. For example, testing for *DPYD* before starting therapy with capecitabine or 5-fluorouracil is routine care in The Netherlands and supported by a consistent body of evidence \[[@CR8]--[@CR10]\]. The impact of PGx in this drug-gene combination is considered high as DPD-deficient patients receiving a normal dose of capecitabine have a high risk for severe toxicities \[[@CR8]\]. Nowadays, genotyping platforms allow for simultaneous characterization of multiple genes. This approach has been evaluated in multiple studies in secondary centers \[[@CR11]--[@CR16]\]. Results indicate that \> 95% of all individuals carry at least one actionable phenotype when tested for a panel of up to 12 genes (including, e.g., *CYP2C9*, *CYP2C19*, *CYP2D6*, *SLCO1B1*, and *VKORC1*) \[[@CR17]--[@CR19]\]. This panel-based approach has also been favorably evaluated in a number of small pilot studies in a primary care setting \[[@CR20]--[@CR22]\].

Most drugs frequently prescribed in primary care are not considered high risk. However, the combination of a high prescription volume and a high frequency of actionable phenotypes of the associated genes may also have resulted in a high total impact on the population of patients \[[@CR23], [@CR24]\]. In this study, we set out to make a quantitative estimate of the potential impact of implementing PGx in primary care by calculating the number of new prescriptions in The Netherlands that comprise a gene-drug pair that is considered actionable by the DPWG. Additionally, we investigated the frequency of prescriptions where a change in choice of drug or dosage would have been required at the start of therapy as described in the guidelines of the DPWG based on a prediction of their genetic predicted phenotype.

Methods {#Sec2}
=======

Selection of drug-gene interactions and classification of therapeutic recommendations {#Sec3}
-------------------------------------------------------------------------------------

The methodology for guideline development of the DPWG has been described in detail previously \[[@CR5]--[@CR7]\]. For this study, the DPWG guidelines were reviewed for drugs with an actionable therapeutic recommendation for a least one phenotype. Therapeutic recommendations were classified in no action, lower dose, higher dose, alternate drug, additional clinical monitoring of the patient, optional lower dose, optional higher dose, and a maximum dose threshold. Additionally, the guidelines were checked to see whether the therapeutic recommendations were dependent on patient characteristics such as age and concomitant use of other medication. For citalopram and escitalopram, the therapeutic recommendations are dependent on the age of the patient as a lower dose is recommended for patients ≥ 65 years of age \[[@CR5], [@CR6], [@CR25]\]. Secondly, for *SLCO1B1* and atorvastatin, the therapeutic recommendation depends on concomitant use of a CYP3A4 inhibiting drug, i.e., amiodarone, verapamil, or diltiazem. Patients with a *SLCO1B1* 521TC or CC genotype and a CYP3A4 inhibitor are advised to switch to rosuvastatin or pravastatin, whereas in patients without a CYP3A4 inhibitor only increased monitoring for muscle pain is recommended.

Source of nationwide prescription data {#Sec4}
--------------------------------------

The Foundation of Pharmaceutical Statistics (Stichting Farmaceutische Kengetallen, SFK) collects data on dispensed drugs from \~ 95% of all the community pharmacies in The Netherlands \[[@CR26]\]. To this end, patients are assigned an anonymous identification number that allows tracking within the participating community pharmacies \[[@CR26]\]. To this end, patients are assigned an anonymous identification number that allows tracking within the participating community pharmacies \[[@CR26]\]. For this study, dispensing data concerning first prescription for the period January 1--December 31, 2016, were obtained. First prescriptions in The Netherlands are defined by healthcare insurers as the dispensing of a drug that has not been used by the patient in the prior 365 days. For citalopram, escitalopram, and atorvastatin, additional information concerning age, and concomitant medication of the patients were also collected \[[@CR5], [@CR6], [@CR25]\].

Frequencies of genetic predicted phenotypes {#Sec5}
-------------------------------------------

To estimate the potential clinical impact of implementation of preemptive testing for a panel consisting of 8 genes (*CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A5*, *DPYD*, *SLCO1B1*, *TPMT*, and *VKORC1*) related to drugs used in primary care, frequency data obtained in the "Implementation of Pharmacogenetics into Primary Care Project" (IP3) study were used as a representation of the Dutch population \[[@CR24]\]. In short, for the IP3 study, 200 patients receiving a new prescription for a selection of 10 drugs with a known gene-drug interaction were genotyped for a panel of 8 genes and 40 genetic variants (see Additional file [1](#MOESM1){ref-type="media"}) using the Affymetrix Drug Metabolism Enzymes and Transporters (DMET) platform supplemented with a RT-PCR Taqman assay to determine the *CYP2D6* copy-number variation (CNV). The genetic test results were translated to actionable phenotypes (e.g., extensive/normal, intermediate, poor, or ultra-rapid metabolizer or EM, IM, PM, and UM respectively) according to the interpretation tables provided by the DPWG guidelines, and communicated to the general practitioner and pharmacist to perform genotype-guided dosing using clinical decision support \[[@CR24]\]. A comparison to the Genome Of the NetherLands (GONL) dataset, containing 250 Dutch parent-offspring families, showed similar minor allele frequencies (MAF) for the selection of SNPs tested in the IP3 study. Similarly, the MAFs of the SNPs in the Caucasian subpopulation in the IP3 study was comparable to the European non-Finnish population in the gnomAD database. Furthermore, specifically for *CYP2D6*, similar frequencies of genetic predicted phenotypes were recently reported by compiling data from the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines \[[@CR27]\]. All these comparisons show that the population of patients in the IP3 study reflect the ethnic composition of the population in The Netherlands and the study population is a representative sample of the Dutch population \[[@CR28], [@CR29]\]. Additionally, the percentage of patients with at least one genetic variant in the tested multigene panel was comparable to previously reported PGx implementation projects \[[@CR12], [@CR14], [@CR17]--[@CR19]\].

Estimating the clinical impact of PGx in primary care {#Sec6}
-----------------------------------------------------

Frequencies of actionable phenotypes for the eight genes from the IP3 were inferred for the Dutch population. Following this comparison, the genetic data were combined with the prescription data obtained from the SFK. After exclusion of drugs not approved in The Netherlands (warfarin) or primarily used in secondary care (5-fluorouracil, capecitabine, and tegafur), a selection of 45 drugs remained (see Table [1](#Tab1){ref-type="table"}). This final selection was used to estimate the occurrence of actionable gene-drug pairs in daily practice in community pharmacies by multiplying the estimated frequency of actionable phenotypes for each gene with the observed first prescriptions of the related drugs (see Table [2](#Tab2){ref-type="table"}).Table 1Number of incident prescriptions in 2016. An overview of the total number of new prescriptions for drugs with an actionable DPWG recommendation dispensed in Dutch pharmacies in 2016 that supply data to the SFK sorted to drug nameATCDrug nameNo. of first-time prescriptionsB01AA07ACENOCOUMAROL49,934N06AA09AMITRIPTYLINE98,750N05AX12ARIPIPRAZOLE13,869N06BA09ATOMOXETINE1987C10AA05ATORVASTATIN111,840C10BA05ATORVASTATIN AND EZETIMIBE1909L04AX01AZATHIOPRINE6943N06AB04CITALOPRAM56,580N06AA04CLOMIPRAMINE7079B01AC04CLOPIDOGREL98,709R05DA04CODEINE519,728N02AJ06CODEINE AND PARACETAMOL69,300N06AA12DOXEPIN270N06AB10ESCITALOPRAM24,454A02BC05ESOMEPRAZOLE65,370B01AA04FENPROCOUMON12,621N03AB02FENYTOINE828C01BC04FLECAINIDE13,605N05AD01HALOPERIDOL51,217N06AA02IMIPRAMINE988A02BC03LANSOPRAZOLE1536L01BB02MERCAPTOPURINE2598C07AB02METOPROLOL194,724C07BB02METOPROLOL MET THIAZIDE1908M01AE52NAPROXEN AND ESOMEPRAZOLE673N06AA10NORTRIPTYLINE20,717A02BC01OMEPRAZOLE575,353N02AA05OXYCODONE464,799N02AA55OXYCODONE AND NALOXONE82A02BC02PANTOPRAZOLE361,741A02BD04PANTOPRAZOLE, AMOXICILLINE, AND CLARITROMYCINE21,768N06AB05PAROXETINE27,018N05AG02PIMOZIDE1060C01BC03PROPAFENON409N06AB06SERTRALINE28,861C10AA01SIMVASTATIN187,362C10BA02SIMVASTATIN AND EZETIMIBE4888L04AD02TACROLIMUS2722L02BA01TAMOXIFEN10,807L01BB03TIOGUANINE1883N02AX02TRAMADOL357,389N02AJ13TRAMADOL AND PARACETAMOL124,951N06AX16VENLAFAXINE26,603J02AC03VORICONAZOLE891N05AF05ZUCLOPENTHIXOL1873Table 2Overview of inferred gene-drug pairs sorted per gene. An overview of the estimates of the occurrences of gene-drug pairs among 45 drugs frequently prescribed in primary careDrugCount incident prescriptions (total)Actionable phenotypeCount incident prescriptionsType of therapeutic recommendation*CYP2C9* PHENYTOIN\*828EM518No actionIM294Lower dose required at start therapyPM17Lower dose required at start therapy*CYP2C19* CITALOPRAM \< 65 years^\*^41,338EM29,557No actionIM8,888Guard maximum daily dosePM1240Guard maximum daily doseUM1654No action CITALOPRAM ≥ 65 years^\*^15,242EM10,898No actionIM3277Guard maximum daily dosePM457Guard maximum daily doseUM610No action CLOPIDOGREL^\*^98,709EM70,577No actionIM21,222Switch to alternate drug at start therapyPM2961Switch to alternate drug at start therapyUM3948Observe status of patient carefully ESCITALOPRAM \< 65 years^\*^21,427EM15,320No actionIM4607Guard maximum daily dosePM643Guard maximum daily doseUM857No action ESCITALOPRAM ≥ 65 years^\*^3027EM2164No actionIM651Guard maximum daily dosePM91Guard maximum daily doseUM121No action ESOMEPRAZOLE65,370EM46,740No actionIM14,055No actionPM1961No actionUM2615Optional increase of dose ESOMEPRAZOLE AND NAPROXEN673EM481No actionIM145No actionPM20No actionUM27Optional increase of dose LANSOPRAZOLE1536EM1098No actionIM330No actionPM46No actionUM61Optional increase of dose OMEPRAZOLE575,353EM411,377No actionIM123,701No actionPM17,261No actionUM23,014Optional increase of dose PANTOPRAZOLE361,741EM258,645No actionIM77,774No actionPM10,852No actionUM14,470Optional increase of dose PANTOPAC21,768EM15,564No actionIM4680No actionPM653No actionUM871Higher dose required at start therapy SERTRALINE^\*^28,861EM20,636No actionIM6205Guard maximum daily dosePM866Guard maximum daily doseUM1154No action VORICONAZOLE^\*^891EM637No actionIM192Observe status of patient carefullyPM27Observe status of patient carefullyUM36Higher dose required at start therapy*CYP2D6* AMITRIPTYLINE^\*^98,750EM52,338No actionIM39,994Switch to alternate drug at start therapyPM4938Switch to alternate drug at start therapyUM1481Switch to alternate drug at start therapy ARIPIPRAZOLE13,869EM7351No actionIM5617No actionPM693Guard maximum daily doseUM208No action ATOMOXETINE^\*^1987EM1053No actionIM805Optional decrease of dosePM99Optional decrease of doseUM30Observe status of patient carefully CLOMIPRAMINE^\*^7079EM3752No actionIM2867Lower dose required at start therapyPM354Lower dose required at start therapyUM106Switch to alternate drug at start therapy CODEINE^\*^519,728EM275,456No actionIM210,490No actionPM25,986No actionUM7796Switch to alternate drug at start therapy CODEINE AND PARACETAMOL^\*^69,300EM36,729No actionIM28,067Optional increase of dosePM3465Switch to alternate drug at start therapyUM1040Switch to alternate drug at start therapy DOXEPIN^\*^270EM143No actionIM109Lower dose required at start therapyPM14Lower dose required at start therapyUM4Switch to alternate drug at start therapy FLECAINIDE13,605EM7211No actionIM5510Lower dose required at start therapyPM680Lower dose required at start therapyUM204Observe status of patient carefully HALOPERIDOL51,217EM27,145No actionIM20,743No actionPM2561Lower dose required at start therapyUM768Optional increase of dose IMIPRAMINE (TOTAL)988 IMIPRAMINE (CYP2C19 EM, IM, UM)^\*^958EM508No actionIM388Lower dose required at start therapyPM48Lower dose required at start therapyUM14Switch to alternate drug at start therapy IMIPRAMINE (CYP2C19 PM) ^\*^30EM16Lower dose required at start therapyIM12Lower dose required at start therapyPM2Lower dose required at start therapyUM0Switch to alternate drug at start therapy METOPROLOL194,724EM103,204No actionIM78,863Optional decrease of dosePM9736Optional decrease of doseUM2921Optional increase of dose METOPROLOL AND THIAZIDE1908EM1011No actionIM773Optional decrease of dosePM95Optional decrease of doseUM29Optional increase of dose NORTRIPTYLINE^\*^20,717EM10,980No actionIM8390Lower dose required at start therapyPM1036Lower dose required at start therapyUM311Switch to alternate drug at start therapy OXYCODONE464,799EM246,343No actionIM188,244Observe status of patient carefullyPM23,240Observe status of patient carefullyUM6972Observe status of patient carefully OXYCODONE AND NALOXONE82EM43No actionIM33Observe status of patient carefullyPM4Observe status of patient carefullyUM1Observe status of patient carefully PAROXETINE^\*^27,018EM14,320No actionIM10,942No actionPM1351No actionUM405Switch to alternate drug at start therapy PIMOZIDE1060EM562No actionIM429Lower dose required at start therapyPM53Lower dose required at start therapyUM16No action PROPAFENON409EM217No actionIM166Optional decrease of dosePM20Lower dose required at start therapyUM6Observe status of patient carefully TAMOXIFEN^\*^10,807EM5728No actionIM4377Switch to alternate drug at start therapyPM540Switch to alternate drug at start therapyUM162No action TRAMADOL^\*^357,389EM189,416No actionIM144,743Optional increase of dosePM17,869Optional increase of doseUM5361Lower dose required at start therapy TRAMADOL AND PARACETAMOL^\*^124,951EM66,224No actionIM50,605Optional increase of dosePM6248Optional increase of doseUM1874Lower dose required at start therapy VENLAFAXINE26,603EM14,100No actionIM10,774Switch to alternate drug at start therapyPM1330Switch to alternate drug at start therapyUM399Optional increase of dose ZUCLOPENTHIXOL1873EM993No actionIM759Lower dose required at start therapyPM94Lower dose required at start therapyUM28Optional increase of dose*CYP3A5* TACROLIMUS^\*^2722Non-Ex2314No actionHet-Ex395Higher dose required at start therapyHomo-Ex14Higher dose required at start therapy*SLCO1B1* ATORVASTATIN (TOTAL)111,840 ATORVASTATIN (WITHOUT CYP3A4 INHIBITOR)108,400NT (521TT)80,758No actionPT (521TC)25,474Observe status of patient carefullyPT (521CC)2168Observe status of patient carefully ATORVASTATIN (WITH CYP3A4 INHIBITOR)3440NT (521TT)2563No actionPT (521TC)808Switch to alternate drug at start therapyPT (521CC)69Switch to alternate drug at start therapy ATORVASTATIN AND EZETIMIBE1909 ATORVASTATIN AND EZETIMIBE (WITHOUT CYP3A4 INHIBITOR)1739NT (521TT)1296No actionPT (521TC)409Observe status of patient carefullyPT (521CC)35Observe status of patient carefully ATORVASTATIN AND EZETIMIBE (WITH CYP3A4 INHIBITOR)170NT (521TT)127No actionPT (521TC)40Switch to alternate drug at start therapyPT (521CC)3Switch to alternate drug at start therapy SIMVASTATIN^\*^187,362NT (521TT)139,585No actionPT (521TC)44,030Switch to alternate drug at start therapyPT (521CC)3747Switch to alternate drug at start therapy SIMVASTATIN AND EZETIMIBE^\*^4888NT (521TT)3642No actionPT (521TC)1149Switch to alternate drug at start therapyPT (521CC)98Switch to alternate drug at start therapy*TPMT* AZATHIOPRINE^\*^6943EM5867No actionIM1041Lower dose required at start therapyPM35Switch to alternate drug at start therapy MERCAPTOPURINE^\*^2598EM2195No actionIM390Lower dose required at start therapyPM13Switch to alternate drug at start therapy TIOGUANINE^\*^1888EM1591No actionIM282Lower dose required at start therapyPM9Switch to alternate drug at start therapy*VKORC1* ACENOCOUMAROL49,934NS (1173CC)16,478No actionNS (1173CT)25,217No actionHS (1173TT)8239Lower dose required at start therapy FENPROCOUMON12,621NS (1173CC)4165No actionNS (1173CT)6374No actionHS (1173TT)2082Lower dose required at start therapy^\*^Gene-drug interactions with a recommendation both by the DPWG and CPIC*EM* extensive/normal metabolizer, *IM* intermediate metabolizer, *PM* poor metabolizer, *UM* ultra-metabolizer, *Non-Ex* non-expressor, *Het* heterozygous expressor, *HOM* homozygous expressor, *NT* normal transport activity, *PT* poor transport activity, *NS* normal sensitivity, *HS* high sensitivity

Results {#Sec7}
=======

For this analysis, prescription data for the selection of 45 drugs were available from 1882 pharmacies (94.4% of total). In 2016, a total of 3,338,464 unique patients received a total of 3,628,597 new prescriptions for the selected 45 drugs (see Table [1](#Tab1){ref-type="table"}). The distribution of the phenotypes for the eight genes is presented in Fig. [1](#Fig1){ref-type="fig"}. Based on the frequencies of the actionable phenotypes of the eight genes and the amount of 3,628,597 first prescriptions, it can be estimated that in 856,002 new prescriptions (23.6%) a gene-drug pair is present (see Table [2](#Tab2){ref-type="table"}). In 195,691 new prescriptions (= 5.4%), the gene-drug pair requires an action by the prescribing physician or dispensing pharmacists. These actions include lowering the dose (*n* = 43,616), increasing the dose (*n* = 1315), or switching to an alternate drug (*n* = 150,761) as per the recommendations of the DPWG. For the remainder of the prescriptions where an actionable gene-drug pair is present (*n* = 660,311), no direct action is required; however, more intensified monitoring for side effects is recommended (*n* = 250,980), guarding a lower maximum threshold of the prescribed dose designated by the DPWG for specific phenotypes (*n* = 26,924) or a potential decrease (*n* = 90,543) or increase (*n* = 291,863) of the dose in case of observed over- or undertreatment respectively (see Table [2](#Tab2){ref-type="table"}).Fig. 1An overview of the genotype predicted phenotypes observed in the IP3 pilot study. Green: extensive/normal metabolizer (*CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT*) / non-expressor (*CYP3A5*) / normal transporter activity (*SLCO1B1*) / normal sensitivity (*VKORC1*). Orange: intermediate metabolizer (*CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT*) / heterozygous expressor (*CYP3A5*). Red: poor metabolizer (*CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT*) / homozygous expressor (*CYP3A5*) / poor transporter activity (*SLCO1B1*) / high sensitivity (*VKORC1*). Blue: ultra-rapid metabolizer (*CYP2C19 & CYP2D6*) (see Additional file [1](#MOESM1){ref-type="media"} for an overview of the tested variants)

In case all patients treated in primary care received pre-emptive screening for the panel of eight genes, \~ 54 per 1000 first prescriptions would have required an intervention for the selected 45 drugs.

Additionally, healthcare professionals would be required to monitor patients more intensively for side effects or failure of treatment in \~ 236 per 1000 first prescriptions of the drugs included in the selection.

This results in a calculated number needed to genotype of 19 for a required intervention on a first time prescription by a healthcare professional at the start of therapy for this selection of 45 drugs. Of note, this calculated number needed to genotype is likely a conservative estimate as interventions for gene-drug interactions (23.6%) of the "monitor closely" type were not used to calculate the number needed to genotype as it is currently unknown how many interventions are performed in this type of gene-drug interaction.

*CYP2C19* and (es)citalopram {#Sec8}
----------------------------

For the selective serotonin reuptake inhibitors (SSRI) citalopram, escitalopram, and sertraline, the DPWG has provided a lower maximum dose for intermediate and poor metabolizers compared to extensive/normal metabolizers \[[@CR5], [@CR6], [@CR25]\]. However, in contrast to sertraline, the maximum dosages for citalopram and escitalopram have alternate thresholds for patients \< 65 years of age vs. ≥ 65 years. For example, for a patient with a first prescription for citalopram with a poor metabolizer phenotype \< 65 years, the advised maximum daily dose is 20 mg/day, whereas for a patient ≥ 65 years with the same phenotype the advised maximum daily dose is 10 mg/day.

In 41,338 of the 56,580 new prescriptions for citalopram (= 73.1%), the patient was below the age of 65 whereas in 15,424 cases the patient was 65 years or older (= 26.9%). From these data, it can be inferred that in 8888 prescriptions, a patient with an IM phenotype of age under 65 should have received a dose restriction of 30 mg and in 3277 prescriptions a patient with an IM phenotype of age 65+ should have been restricted to a maximum dose of 15 mg. For PMs, the dose should have been maximized to 20 mg in individuals of \< 65 years old (*n* = 1240 prescriptions) and 10 mg for age 65+ (*n* = 457 prescriptions) respectively.

In case of escitalopram, the dose restriction should have been 15 mg (*n* = 4607 prescriptions) and 7.5 mg (*n* = 651 prescriptions) for patients with the IM phenotype in the groups \< 65 and ≥ 65 respectively. In case of 643 patients younger than 65 years of age with the PM phenotype, the dose should have been restricted to 10 mg, whereas in 91 patients of ≥ 65 years with the same inferred phenotype the dose should have been restricted to 5 mg (see Table [2](#Tab2){ref-type="table"}).

*SLCO1B1* and atorvastatin {#Sec9}
--------------------------

The frequency of patients with a reduced transport capacity mediated as a result of genetic variation in the *SLCO1B1* gene was found to be 25.5% of which 23.5% was the result of the 521T/C genotype and 2.0% the result of a 521C/C genotype. In 2016, a total of 113,749 first prescriptions for atorvastatin or atorvastatin combined with ezetimibe were dispensed. Based on the sample of genotype data from the IP3 study, we extrapolated that in 29,006 prescriptions the patient would likely carry the 521T/C or the 521C/C genotype. For these individuals, an additional check for concomitant use of inhibitors of CYP3A4 is required as per the DPWG guidelines and in case of the presence of a CYP3A4 inhibitor healthcare professionals are recommended to switch to an alternate drug.

Discussion {#Sec10}
==========

This study provides an estimate of the potential nationwide clinical impact of a pre-emptive pharmacogenetic panel approach in primary care in The Netherlands. Based on frequencies of actionable phenotypes gathered in a pilot study of 200 patients and nationwide prescription data (*n* = 3,628,597), we inferred that in 23.6% of the first prescriptions of the selected 45 drugs a gene-drug pair is present \[[@CR24]\]. If pre-emptive genetic testing of the panel consisting of eight genes had been performed in this population, we estimate that 5.4% of the new prescriptions an intervention at the start of therapy would have been required and in 18.2% of the new prescriptions the therapeutic recommendations of the DPWG advise more intense clinical monitoring of the patient with an optional dose adjustment in case of suboptimal therapy. An example of such a recommendation is the optional increase in dose of a proton pump inhibitor in a *CYP2C19* ultra-rapid metabolizer.

A strength of this study is that the dataset used to calculate the frequency of gene-drug pairs compasses 1882 pharmacies (94.4% of total) and reflects all community pharmacies in The Netherlands \[[@CR26]\]. This allows for a detailed view of the medication use of the total population treated in primary care and provides accurate data of the number of first prescriptions of one of the PGx drugs where patients have not yet reached their maintenance therapy as a result of empirical dosing by general practitioners. In a similar study by Samwald et al., prescription data from a combination of sources (private insurance, Medicaid or Medicare) were used \[[@CR30]\]. Whereas the dataset used in that study encompasses a considerable larger number of patients, it is at risk for selection bias as it is restricted to selected groups within the population of the USA \[[@CR30]\].

Although the data in this analysis encompasses 94.4% of the pharmacies in The Netherlands and provides a detailed view of drug use in primary care, other sections of pharmaceutical care are not represented in this dataset. A majority of the 5.6% of pharmacies that do not supply data to the database of the SFK are mainly outpatient pharmacies (community pharmacies as part of a hospital). In comparison with community pharmacies, the outpatient pharmacies often dispense more specialized pharmacotherapy, for example HIV therapy. For example, this may result in a higher frequency of drug-drug interactions through CYP3A4 and higher frequency of relevant drug-drug-gene interactions for statins. The number of first prescriptions where a patient uses a CYP3A4 inhibitor may likely be an underestimation of the reality.

Another limitation to this study is the lack of complete clinical data (such as comorbidities, reduced clearance of drugs, and information on indications) in the available dataset. For a limited number of gene-drug interactions, the therapeutic recommendation of the DPWG is co-dependent on these clinical data and co-medication. Unfortunately, our dataset only contained information about age, gender, and co-medication with CYP3A4 inhibitors. As a result, estimates for gene-drug interaction requiring interpretation of additional clinical factors or information about indication to support decision making might differ from reality. For example, in case of the interaction of simvastatin and the *SLCO1B1* 521TC genotype, the primary recommendation is to switch to an alternate therapy (used in this analysis to infer therapeutic interventions). However, if the prescribed dose is ≤ 40 mg simvastatin, the recommendation is to continue simvastatin provided the patient carries no additional risk for statin-induced myopathy. Additional risk factors include hepatic or renal impairment, co-medication with CYP3A4 inhibitors, co-medication with SLCO1B1 inhibitors, female gender, old age (≥ 65) or hypothyroidism \[[@CR7], [@CR25]\]. To estimate the potential impact of clinical factors on the number of patients requiring an intervention, we conducted a sensitivity analyses for these risk factors (excluding co-medication with SLCO1B1 inhibitors) for both simvastatin and atorvastatin.

Based on the genotype frequencies inferred from the IP3 study and the SFK prescription data, out of all the first-time prescriptions for simvastatin, 44,030 individuals carried the *SLCO1B1* 521TC genotype (see Table [2](#Tab2){ref-type="table"}). Using publicly available data on prevalence of relevant co-factors, we estimate that \~ 10,000 males with the 521TC genotype without any risk factors are present where the recommendation would be to continue therapy with 40 mg simvastatin \[[@CR31], [@CR32]\]. A similar sensitivity analysis was carried out for the patients receiving simvastatin with ezetimibe. The initial analysis identified 1149 patients who would require a switch based on their inferred *SLCO-1B1* 521TC genotype (see Table [2](#Tab2){ref-type="table"}). Using the same sensitivity analysis used for simvastatin, we estimate approximately 266 individuals with the 521TC genotype do not carry additional risk factors and do not require a change in therapy.

For atorvastatin, the data presented in Table [2](#Tab2){ref-type="table"} may be an underestimation of the trough number of switches required in clinical practice. In contrast to simvastatin, the consideration of clinical co-factors would result in additional switches. The sensitivity analysis for atorvastatin identified 6160 male patients without additional risk factors who are recommended to start atorvastatin with the normal dose from the total 27,642 patients with 521TC and CC genotypes. In contrast, in a group of \~ 21,000 patients, atorvastatin should be switched to an alternate therapy due to the existence additional risk factors identified by the DPWG. A similar analysis for the combination of atorvastatin with ezetimibe shows 83 patients with the 521TC or CC genotype without risk factors who can start therapy with the ezetimibe/atorvastatin combination, while in 289 patients with these genotypes additional risk factors are present likely resulting in a switch to an alternate cholesterol-lowering therapy. Overall, the results of both our sensitivity analysis indicate that without accounting for additional clinical factors for the gene-drug interactions concerning *SCLO1B1*, our estimates of 195,691 patients requiring an intervention is conservative and could be as high as \~ 206,981.

Additionally, due to the structure of the obtained prescription data, the analysis in this study was performed from the perspective of prescriptions within the time frame of a year. The IP3 study (used for this analysis) and multiple other studies using panel-based pharmacogenetic testing show that patients often carry multiple actionable pharmacogenes \[[@CR17]--[@CR19], [@CR24]\]. In reality, physicians and pharmacists will thus likely encounter multiple actionable phenotypes in the same patient and due to polypharmacy are likely to encounter multiple gene-drug interactions in each patient \[[@CR33]\]. Additional follow-up of the IP3 study indeed showed that within 2.5-year follow-up, 97% of the included patients received a prescription for a newly initiated drug with an actionable DGI, while 33% of the patients received up to four new prescriptions with known gene-drug interactions. In the newly started prescriptions in our cohort, 24.2% of the patients indeed carried the actionable phenotype, requiring an intervention by the pharmacist \[[@CR34]\]. These data show that an increase in the studied timeframe will show a larger impact on healthcare. However, our results indicate that pre-emptive PGx testing for a panel of eight genes can already have significant impact on first prescriptions within the timeframe of a single year. Results of such a PGx test can be re-used over the entire lifespan of an individual. It is highly likely that impact will be even larger in reality as 13.5% of the patients that visit (Dutch) community pharmacies use ≥ 5 drugs from different ATC3 classes \[[@CR26]\]. Moreover, due to the increase in the proportion of elderly (≥ 65 years), the number of polypharmacy patients will likely increase in the future, increasing the possible impact of a pharmacogenomics panel \[[@CR26]\].

As a result of the use of a PGx panel with a limited number of pharmacogenes, this may lead to an underestimate of the potential impact of PGx in primary care in The Netherlands. After the initiation of the IP3 pilot study, the DPWG has published additional guidelines on gene-drug pairs other than *CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT*, and *VKORC1* existing on the DMET micro-array platform but not included in this panel (e.g., *CYP1A2*, *CYP2B6*, and *UGT1A1*) \[[@CR24]\]. In addition, the chosen platform in the pilot study does not encompass all genes deemed relevant by the DPWG such as *FVL* and *HLA* genes. Of note, this study only encompasses interventions based on therapeutic recommendations for gene-drug interactions described in the guidelines of the DPWG as they are incorporated in the clinical decision support systems of healthcare professionals in The Netherlands. In clinical practice, the Dutch clinicians will thus most likely only use the therapeutic recommendations by the DPWG. In countries where the guidelines of the CPIC are used to guide pharmacotherapy, the number of prescriptions with a combination of actionable phenotypes and associated drugs will likely differ somewhat as the DPWG has provided therapeutic recommendations for certain gene-drug interactions that are not covered by CPIC and vice versa. However, a recent systematic comparison of the guidelines of the CPIC and the DPWG found that a selection of 27 well-known gene-drug interactions (all included in the selection of this study) was covered by both consortia and the two consortia provided similar therapeutic recommendations for these gene-drug interactions \[[@CR7]\].

Similar to the Ubiquitous Pharmacogenomics (U-PGx) project, current genotyping initiatives using a pre-emptive panel approach should use a platform which provides an extensive panel and is flexible (such as the QuantStudio 12K Flex Real-Time PCR System by Thermo Fisher Scientific or the SNPline by LGC Group) to allow for adjusting if new guidelines are published by CPIC or the DPWG \[[@CR35]\].

Currently, the implementation of PGx in primary care remains low in The Netherlands as shown by a recent survey among Dutch pharmacists that showed 14.7% adoption of PGx testing, despite the existence of guidelines containing therapeutic recommendations and their integration into the workflow of healthcare professionals \[[@CR5], [@CR6], [@CR36]\]. In part, this may be explained by the fact that not all healthcare professionals are aware of the existence of clinical decision support in electronic medication surveillance systems. A recent survey among pharmacists showed that 65.4% were aware that clinical decision support contained therapeutic recommendations for genetic predicted phenotypes \[[@CR36]\]. The potential of PGx has grown, but probably other healthcare professionals (such as physicians) are less aware of the state in which PGx is already available in their workflow. Finally, the clinical utility and cost-effectiveness of pre-emptive panel-based screening for PGx variants has only been shown in small pilot studies, but large clinical trials providing the required evidence are still lacking \[[@CR20]--[@CR22]\]. Initiatives such as the U-PGx, a multinational consortium implementing a model of pre-emptive PGx-testing in healthcare environments in seven European nations, will investigate whether upfront implementation of a panel-based pharmacogenetic screening can lead to better patient outcomes in a cost-effective manner \[[@CR35]\].

Conclusions {#Sec11}
===========

Based on the data presented in this study, it can be concluded that an actionable gene-drug interaction is present in approximately one out of four new prescriptions for a drug classified by the DPWG guidelines as requiring therapeutic intervention. Should all patients with a new prescription for this selection of drugs have been pre-emptively genotyped, 1 out of every 19 new prescriptions could have been adjusted based on the genetic test result. Consequently, with an anticipated near future where healthcare professionals will be confronted with results of PGx panels, adjusting pharmacotherapy as a result of relevant gene-drug interaction will likely become a routine task in drug prescribing.
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Additional file 1:Overview of tested PGx variants. Description of data: An overview of the PGx variants included in the panel used in the Implementation of Pharmacogenetics into Primary Care Project (IP3) study. (DOCX 16 kb)

We would like to thank F. van Tienen for his assistance in the data analysis of this study.

Funding {#FPar1}
=======

This work was supported by unrestricted grants from The Royal Dutch Pharmacist's Association, The Hague (KNMP), The Netherlands, and Zorg & Zekerheid, Leiden, The Netherlands.

Availability of data and materials {#FPar2}
==================================

The dataset generated in the IP3 study are available in the Leiden Open (source) Variation Database.

PB, JS, and HJG designed the research. PB performed the research. PB and JS analyzed the data. PB, JS and HJG wrote the manuscript. All authors read and approved the final manuscript.

The central Medical Ethics Review board of the Leiden University Medical Center (LUMC) in Leiden, The Netherlands, approved the protocol of the IP3 study.

Not applicable.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
